International Journal of Hematology and Oncology 2023, Vol 33, Num 1 Page(s): 233-238
Survival Following Stereotactic Radiotherapy for Recurrent High Grade Gliomas

Gulcin ERTAS1, Ali R. UCER1, Yıldız Y. GUNEY1, Gulhan G. AVCI1, M. Bedri ALTUNDAG1, Hayati ABANUZ1, Atilla DEMIRKASIMOGLU1, Tamer CALIKOGLU1

Ankara Oncology Training and Research Hospital, Department of Radiation Oncology, Ankara, TURKEY

Keywords: Cyberknife, Glioma, Stereotactic radiotherapy
We aimed to report our stereotactic radiotherapy experience with Cyberknife (Accuray, Inc., Sunnyvale, CA, USA) for patients with recurrent high grade glial tumor. Forty-two patients with histologically proven malign glioma (30 glioblastoma, 12 anaplastic astrocytoma) and also treated with previous conventional fractioned radiotherapy underwent stereotactic radiotherapy via Cyberknife for their recurrent tumor in Ankara Oncology Hospital between July 2009-and September 2012. The median follow up time was 30 months (range, 8-144 months) after diagnosis and 10 months (range, 1-38 months) from stereotactic radiotherapy (SRT). The median survival from SRT are 8 months for glioblastoma patients and 11 months for grade 3 malign glioma patients (p= 0.157). The median survival from SRT are 9 months and 11 months in patients given chemotherapy and not given, respectively (p= 0.436). The median survival from SRT are 10 months in patients reoperated and 9 months not reoperated ( p= 0.827). Stereotactic radiotherapy is an effective treatment modality in patients with recurrent glial tumor.